Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that new data from across its oncology portfolio will be presented in 15 accepted abstracts at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. These presentations span the cancer care treatment continuum, from minimal residual disease (MRD) detection and recurrence monitoring to advanced-stage tumor profiling and therapy response assessment.

Guardant Health's accepted abstracts span multiple tumor types, including lung, colorectal, breast, head and neck, and cancers of unknown primary. Together, they underscore the company's commitment to harnessing cutting-edge genomic and epigenomic insights to improve outcomes for patients across all stages of disease.

"We are proud that Guardant's novel technologies and research collaborations are featured across multiple abstracts at ESMO this year," said Dr. Craig Eagle, Guardant Health Chief Medical Officer. "These studies highlight how our technologies are helping to advance precision oncology—from catching recurrence earlier, to guiding optimal therapy choices, to monitoring treatment effectiveness across a wide range of cancers."

Highlights include:

• Novel applications of Guardant Infinity™ in tumor profiling: data from the SIBYL study highlight the ability of molecular lung subtyping to refine histologic characterization and associated decision-making in non-small cell lung cancer while findings from the CUPIDO study underscore the utility of molecular tumor typingto provide insights for cancers of unknown primary, addressing a major unmet clinical need.
• Therapy monitoring in advanced cancer: updated results from the CROWN study demonstrate how Guardant Reveal can track treatment response in anaplastic lymphoma kinase positive (ALK+) lung cancer, utilizing ctDNA analysis to gain a deeper understanding of how patients are responding to therapy.
• Advancing MRD detection and recurrence monitoring: Results from the PEGASUS, PRECISION, and decision impact studies in colorectal cancer, as well as new data in head and neck cancers from two independent studies demonstrate the performance and utility of Guardant Reveal™ in early detection of recurrence and guiding treatment decisions.
• New data on fibroblast growth factor receptors (FGFR) alterations as an emerging biomarker in non-small cell lung cancer (NSCLC), comparing Guardant360 Liquid detection rates with known tissue-based datasets.

The full list of Guardant Health 2025 ESMO Posters and Presentations